School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
J Neurol Sci. 2017 Oct 15;381:41-54. doi: 10.1016/j.jns.2017.08.012. Epub 2017 Aug 12.
AIM: The clinical aim was to provide up-to-date evidence-based recommendations for the treatment of MS-related fatigue (MSRF). The scientific aim was to prioritise topics for future randomised clinical trials with sufficient power. METHODS: A systematic search of review based research that considered MSRF in adults (18years and over) was undertaken in May 2016. Data from reviews was extracted, critically appraised and synthesised using four specific techniques. RESULTS: A total of 24 reviews were identified (17 non-pharmacological, 5 pharmacological, 2 combining both), which contained 339 studies on interventions deigned to improve MSRF. The methodological quality of the reviews was identified by an average AMSTAR score of 6.5 (SD=1.87: 95% CI=5.75-7.25). No pharmacological intervention had strong evidence for improving MSRF. Limited/conflicting evidence was found for Amantadine and Prokarin and potential benefits for Modafinil were identified. Pemoline and Carnitine contained unclear/no evidence for fatigue management. Non-pharmacological interventions produced mixed conclusions regarding the effectiveness of the intervention to improve MSRF. Education (energy conservation and fatigue management) and exercise had supporting evidence for reducing MSRF but mixed conclusions gathered from subtypes of exercise. Reviews considering psycho-behavioural interventions (CBT and mindfulness) had limited information considering effectiveness. Finally, a single intervention combining physical and cognitive strategies showed more promising results. CONCLUSION: Further research into Pharmacological interventions for MSRF is required notably considering the potential of Modafinil. Yoga and energy conservation/fatigue management programs had strong evidence supporting use in management of MSRF. Due to the dissimilar interventions used in combined training the subtype of exercise cannot be recommended. Future research into Amantadine, psycho-behavioural interventions is vital to justify the current National Institute for Health and Care Excellence guidelines. The methodological quality of studies inhibited the ability of this review to provide other recommendations.
目的:本临床研究旨在为治疗多发性硬化症相关性疲劳(MSRF)提供最新的基于循证的推荐意见。科学目的是确定具有足够效能的未来随机临床试验的优先主题。
方法:本研究于 2016 年 5 月对考虑成人(18 岁及以上)MSRF 的基于综述的研究进行了系统检索。从综述中提取数据,并使用四种特定技术对其进行严格评价和综合分析。
结果:共确定了 24 篇综述(17 篇非药物治疗,5 篇药物治疗,2 篇同时涉及两者),其中包含了 339 项旨在改善 MSRF 的干预措施研究。综述的方法学质量通过平均 AMSTAR 评分 6.5(SD=1.87:95%CI=5.75-7.25)来确定。没有药物干预措施具有改善 MSRF 的强有力证据。金刚烷胺和普罗卡林的疗效证据有限/相互矛盾,而莫达非尼可能具有益处。哌甲酯和肉毒碱在疲劳管理方面证据不明确/无证据。非药物干预措施对改善 MSRF 的有效性的结论存在差异。教育(能量节约和疲劳管理)和运动有证据支持减轻 MSRF,但从运动的亚类中得出的结论存在差异。考虑心理行为干预(CBT 和正念)的综述考虑有效性的信息有限。最后,一项结合身体和认知策略的单一干预措施显示出更有希望的结果。
结论:需要对 MSRF 的药物干预措施进行进一步研究,尤其是考虑莫达非尼的潜力。瑜伽和能量节约/疲劳管理方案具有支持其用于管理 MSRF 的有力证据。由于联合训练中使用的干预措施不同,因此不能推荐特定的运动类型。对金刚烷胺和心理行为干预的未来研究对于证实当前国家卫生与临床优化研究所的指南至关重要。研究方法的质量限制了本综述提供其他建议的能力。
Cochrane Database Syst Rev. 2012-1-18
Cochrane Database Syst Rev. 2017-4-7
Health Technol Assess. 2000
Nurs Stand. 2015-6-24
Expert Opin Pharmacother. 2012-1-6
Br J Occup Ther. 2023-6
Mult Scler J Exp Transl Clin. 2025-2-13
J Neural Transm (Vienna). 2025-1
Front Immunol. 2024-4-5
Cureus. 2023-7-19
Healthc Inform Res. 2022-10